Bolt Biotherapeutics Inc BOLT.OQ BOLT.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The Redwood City California-based company is expected to report a 36.5% decrease in revenue to $725 thousand from $1.14 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Bolt Biotherapeutics Inc is for a loss of $5.79 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $13.50, about 64.6% above its last closing price of $4.78
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -6.50 | -6.45 | -4.46 | Beat | 30.9 |
Mar. 31 2025 | -7.14 | -7.25 | -5.80 | Beat | 20 |
Dec. 31 2024 | -7.60 | -7.60 | Met | 0 | |
Sep. 30 2024 | -6.71 | -7.05 | -8.00 | Missed | -13.5 |
Jun. 30 2024 | -10.44 | -9.60 | -9.20 | Beat | 4.2 |
Mar. 31 2024 | -9.98 | -10.20 | -5.60 | Beat | 45.1 |
Dec. 31 2023 | -8.84 | -9.63 | -9.40 | Beat | 2.4 |
Sep. 30 2023 | -9.96 | -10.00 | -8.60 | Beat | 14 |
This summary was machine generated November 7 at 11:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments